M. Pladevall-Vila

First name

M.

Last name

Pladevall-Vila

Johannes, C. B., Beachler, D. C., Layton, J. B., Danysh, H. E., Ziemiecki, R., Arana, A., et al. (2022). Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01263-3

View

Danysh, H. E., Johannes, C. B., Beachler, D. C., Layton, J. B., Ziemiecki, R., Arana, A., et al. (2022). Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01262-4

View

Willame, C., Rosillon, D., Zima, J., Angelo, M. G., Stuurman, A. L., Vroling, H., et al. (2016). Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother. http://doi.org/10.1080/21645515.2016.1199308

View

Cainzos-Achirica, M., Varas-Lorenzo, C., Pottegard, A., Asmar, J., Plana, E., Rasmussen, L., et al. (2018). Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: A case study of dabigatran etexilate in Europe. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4416

View